WuXi and Lilly Collaborate on China Development of Cardiovascular Drug

WuXi PharmaTech and Eli Lilly will collaborate on China development of a novel, once-daily oral agent, discovered by Lilly and aimed at alleviating cardiovascular risk in patients with dyslipidemia. The drug candidate is designed to reduce cardiovascular events in patients with elevated LDL cholesterol and triglycerides who are at risk for heart attacks or strokes. WuXi will be responsible for regulatory, development and manufacturing activities in China, while Lilly will market the drug. Both companies will invest in the project. More details.... Stock Symbols: (NYSE: WX) (NYSE: LLY) Share this with colleagues: // //